Navigation Links
Archimedes Pharma Launches Lazanda® - the Only Fentanyl Nasal Spray for the Management of Breakthrough Pain in Cancer in the U.S.
Date:10/17/2011

ence at 30 minutes (SPID30). More than 500 patients evaluated in the clinical trial program (which included three phase III clinical trials) contributed to the understanding of the tolerability and safety profile of Lazanda. The most common adverse events associated with Lazanda were consistent with opioid treatment and included vomiting, nausea, pyrexia (fever), and constipation.IMPORTANT SAFETY INFORMATION WARNINGS: POTENTIAL FOR ABUSE and IMPORTANCE OF PROPER PATIENT SELECTIONLazanda® contains fentanyl, an opioid agonist and a Schedule II controlled substance, with an abuse liability similar to other opioid analgesics. Lazanda can be abused in a manner similar to other opioid agonists, legal or illicit. Consider the potential for abuse when prescribing or dispensing Lazanda in situations where the physician or pharmacist is concerned about an increased risk of misuse, abuse, or diversion. Schedule II opioid substances, which include morphine, oxycodone, hydromorphone, oxymorphone, and methadone, have the highest potential for abuse and risk of fatal overdose due to respiratory depression. Serious adverse events, including deaths, in patients treated with other oral transmucosal fentanyl products have been reported.  Deaths occurred as a result of improper patient selection (e.g., use in opioid non-tolerant patients) and/or improper dosing. The substitution of Lazanda for any other fentanyl product may result in fatal overdose.Lazanda is indicated only for the management of breakthrough pain in cancer patients 18 years of age and older who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. Patients considered opioid tolerant are those who are taking at least 60 mg of oral morphine/day, 25 mcg of transdermal fentanyl/hour, 30 mg of oxycodone/day, 8 mg oral hydromorphone/day, 25 mg oral oxymorphone/day, or an equianalgesic dose of another opioid for one week or longer. Lazanda is
'/>"/>

SOURCE Archimedes Pharma Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Archimedes Pharma Announces Publication of Long-Term Safety and Tolerability Clinical Study of Fentanyl Pectin Nasal Spray (FPNS) in the Journal of Opioid Management
2. Archimedes Pharma Announces Publication of a Pivotal Clinical Study of Fentanyl Pectin Nasal Spray (FPNS) in Pain, the Peer-Reviewed Journal from the International Association for the Study of Pain
3. Archimedes Pharma Receives CHMP Positive Opinion for PecFent(R) for the Treatment of Breakthrough Cancer Pain
4. Archimedes Pharma Announces Successful Proof-of-Concept Results on Two Intranasal Development Projects
5. Novo Nordisk A/S: PharmaVitae Profile
6. Auxilium Pharmaceuticals to Announce Third Quarter 2011 Results and Conduct Conference Call on Monday, October 31, 2011
7. Par Pharmaceutical Files Declaratory Judgment to Protect First Amendment Rights to Disseminate Truthful Information Regarding Megace® ES
8. Reata Pharmaceuticals Adds Executives to Management Team and Board of Directors
9. Access Pharmaceuticals Updates MuGard Website with New Video Featuring Clinical Feedback and Manufacturing Footage
10. CVS/pharmacy Ready to Provide Assistance During Medicare Part D Annual Enrollment Period
11. ShangPharma Corporation Announces Shareholder Resolutions Adopted at 2011 Annual General Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  CytoSorbents Corporation (NASDAQ CM: ... CytoSorb® extracorporeal cytokine adsorber to reduce deadly inflammation ... receipt of $385,642, net of transaction costs, in ... Technology Business Tax Certificate Transfer Program sponsored by ...
(Date:1/23/2015)... BOSTON , January 23, 2015 Heptares ... is delighted to announce that the Malcolm Campbell ... Congreve (Vice President of Chemistry), Fiona Marshall ... (Chief Executive Officer and co-founder) for the seminal contributions to ...
(Date:1/22/2015)... Colo. , Jan. 22, 2015  BiOptix is pleased ... as Vice President of Chemistry and Biochemistry. Scott joins ... Pharmaceuticals, AstraZeneca Pharmaceuticals, and Amgen throughout the course of ... development. "Scott is a nationally recognized thought ...
Breaking Medicine Technology:CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2
... NeurogesX, Inc. (Nasdaq: NGSX ), a biopharmaceutical ... announced that it has entered into a $20 million ... HTGC).  The loan agreement includes both a $5 million ... term loan. Proceeds are expected to be ...
... Aug. 8, 2011 Global Health Ventures Inc. ... on sublingual drug delivery announced today that their August ... and CEO, is available for on-demand viewing. ... watch event now" button. Their presentation will ...
Cached Medicine Technology:NeurogesX, Inc. Secures $20 Million Debt Facility 2NeurogesX, Inc. Secures $20 Million Debt Facility 3NeurogesX, Inc. Secures $20 Million Debt Facility 4Global Health Ventures August 4th Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com 2
(Date:1/22/2015)... Recently, Weddingshe.com has added many trendy Champagne ... highest annual revenues in the past three years. Today, the ... dresses. , According to the sales manager of the company, ... them in 2015. This point can be reflected on the ...
(Date:1/22/2015)... Payday lending practices in four southern states ... distress to the states that permit them, according to ... on Race and Wealth. , While they generate hundreds ... at the same time substantially depress economic activity, according ...
(Date:1/22/2015)... JJsHouse.com is a famous dress online store for ... its latest collection of wedding dresses , and launches ... is the wedding dress on your big day; the wedding ... Every bride wants to find the most suitable wedding dress. ...
(Date:1/22/2015)... Step into a macabre world where plants ... Virginia. Wicked Plants, the Museum’s latest featured exhibition, opens ... carnivorous and diabolical plants inside of a dilapidated, Victorian ... biochemical, physical and neurological processes between botanicals and the ...
(Date:12/26/2014)... It is said that nothing makes a lady feel ... wedding dress supplier, shows its new selection of navy ... , UWDress.com’s navy cocktail gowns are the cornerstones of ... fashion styles. Simple dresses in bright neon colors can be ...
Breaking Medicine News(10 mins):Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2Health News:Wicked Plants are taking over the Science Museum of Virginia 2Health News:UWDress.com Shows Its New Navy Cocktail Dresses For 2015 2
... and Industry Thought Leader Joins Healthcare ... Management Consulting Practice, ... to announce the appointment of Ogan Gurel, M.D. as a ... have Dr. Gurel join our team," said Vip Jain - ...
... BET Networks, national HIV/AIDS,public awareness initiative Rap-It-Up returns ... health forums throughout New York City and Newark,N.J., to ... young adults; as well as the rise of HIV/AIDS ... organization Hip,Hop 4 Life and local radio station Hot ...
... to succeed in reducing prevalance of obesity,among children ... intervention and,education, MEMPHIS, Tenn., Nov. 7 ... at St. Jude Children,s,Research Hospital is the first ... in reducing the prevalence of overweight children, according ...
... businesses for its commitment to building a culture of ... ... The American Heart Association,recently recognized Regence as a Start! ... in the workplace and helping,employees live healthier lives. The company ...
... Million ... Million, SUNNYVALE, Calif., Nov. 7 Accuray,Incorporated (Nasdaq: ... announced financial results for the first quarter of fiscal 2008,ended ... 2008, Accuray reported record total,revenue of $48.6 million, up 48 ...
... ... Exploration Process, GERMANTOWN, Md., Nov. ... company focused on,developing and commercializing novel anti-infective products, announced an,agreement ... Company,s largest equity shareholders, raising up to $10 million in,cash. ...
Cached Medicine News:Health News:XRoads Solutions Group Appoints Dr. Ogan Gurel as Managing Director 2Health News:BET Networks' Award-Winning Rap-It-Up HIV/AIDS Campaign Returns to New York City for The Youth Empowerment Tour on November 13-16 2Health News:BET Networks' Award-Winning Rap-It-Up HIV/AIDS Campaign Returns to New York City for The Youth Empowerment Tour on November 13-16 3Health News:St. Jude Program Reduces Weight Gain in Young African-American Girls 2Health News:St. Jude Program Reduces Weight Gain in Young African-American Girls 3Health News:American Heart Association Award Recognizes Regence as a Start! Fit-Friendly Company 2Health News:American Heart Association Award Recognizes Regence as a Start! Fit-Friendly Company 3Health News:Accuray Reports Record Revenue in First Quarter of Fiscal 2008 2Health News:Accuray Reports Record Revenue in First Quarter of Fiscal 2008 3Health News:Accuray Reports Record Revenue in First Quarter of Fiscal 2008 4Health News:Accuray Reports Record Revenue in First Quarter of Fiscal 2008 5Health News:Accuray Reports Record Revenue in First Quarter of Fiscal 2008 6Health News:Accuray Reports Record Revenue in First Quarter of Fiscal 2008 7Health News:Accuray Reports Record Revenue in First Quarter of Fiscal 2008 8Health News:MiddleBrook Pharmaceuticals Raises Up to $10 Million from Deerfield Management 2Health News:MiddleBrook Pharmaceuticals Raises Up to $10 Million from Deerfield Management 3Health News:MiddleBrook Pharmaceuticals Raises Up to $10 Million from Deerfield Management 4Health News:MiddleBrook Pharmaceuticals Raises Up to $10 Million from Deerfield Management 5
... Bio-Quant S. typhi rapid test is ... The test employs a conation of ... polyclonal antibody immobilized on the solid ... typhi,antigen associated Salmonella typhi (typhoid) infection ...
... Mono is an immunochromatographic in vitro ... with,infectious mononucleosis infection.,Infectious mononucleosis (IM) is ... of IM is based on detection ... such as the,heterophile antibodies present in ...
OneStep Midstream Urine hCG Pregnancy InstaTest is a test kit for the determination of hCG(Human Chorionic Gonadotropin) in urine specimens. This test kit is used to obtain a visual, qualitative resu...
... Myoglobin Insta Test is an ... test. It is designed for ... serum specimens. The presence of ... ng/mL or higher can be ...
Medicine Products: